Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zhong Ji Longevity Science Group Limited ( (HK:0767) ) has provided an update.
Zhong Ji Longevity Science Group Limited has announced an extension of the expiry date for its Memorandum of Understanding (MOU) regarding the potential acquisition of Asian Integrated Cell Laboratory Limited. This extension, until December 2, 2025, allows more time for due diligence and assessment. The target company collaborates with Bright Cells Inc. to conduct FDA-approved clinical research on stem cells, aiming to develop treatments for aging-related frailty and premature ovarian failure across various regions. The acquisition, if completed, could significantly impact the company’s market position and stakeholder interests.
More about Zhong Ji Longevity Science Group Limited
Zhong Ji Longevity Science Group Limited operates in the biotechnology industry, focusing on the development of cell therapy technologies. The company is involved in clinical research and development of stem cell pharmaceuticals, collaborating with international partners to advance treatments for aging-related conditions and other health issues.
Average Trading Volume: 1,479,512
Technical Sentiment Signal: Hold
Current Market Cap: HK$401.1M
For a thorough assessment of 0767 stock, go to TipRanks’ Stock Analysis page.